A U.S. based pharmaceutical client approached Freyr for the submission of withdrawal of ANDA to the USFDA and payment of facility fee as per Generic Drug User Fee Amendments (GDUFA).
Read this case to know how Freyr carried the entire process.
Fill the form below to download the Case Study
